A patient sat in my office last month and described something I’ve now heard a dozen times in the past year. She’d been bulimic for almost twenty years — the binge, the panic, the purge, the shame, the white-knuckle hours of trying not to repeat it. Three weeks into a low dose of semaglutide, prescribed for weight management by another physician who had no idea what she was actually struggling with, the cycle had stopped. Not slowed. Stopped. She wasn’t sure whether to feel relieved or terrified.
This is the conversation I’m having more and more often. GLP-1 agonists for bulimia — Ozempic, Wegovy, Mounjaro, Zepbound — have arrived in my practice ahead of the formal evidence base, and ignoring that reality serves no one. So here’s what I’m actually doing in the room with patients in Palm Beach, what I’m watching for, and where I draw the lines.
Why These Drugs Touch Bulimia at All
GLP-1 (glucagon-like peptide-1) receptor agonists were designed for type 2 diabetes and obesity. They slow gastric emptying, blunt appetite, and — crucially for our purposes — appear to dampen the dopamine-driven reward signals that make hyperpalatable foods so compelling. That last mechanism is what overlaps with the neurobiology of bulimia.
A patient with bulimia isn’t simply someone who eats too much and panics about it. The binge phase is a dopamine-driven event — the brain’s reward circuitry locked onto food the same way an addicted brain locks onto a substance. The compulsion is real. The lack of control is real. And for the first time, we have medications that seem to interrupt that loop at the level of the receptor.
Clinically, what patients describe is striking. They use phrases like “the food noise stopped,” “I just forgot about it,” “I didn’t want it anymore.” That language is very close to what I hear from patients on naltrexone for alcohol use disorder. Different drug, similar quieting.
What the Evidence Actually Shows
I want to be honest with you: the evidence base for GLP-1s in bulimia specifically is thin. Most of the published data is on binge eating disorder (BED), which overlaps with bulimia but isn’t identical. Small studies of semaglutide and liraglutide show reductions in binge episodes, food cravings, and eating-disorder symptom scores. Trials of tirzepatide (Mounjaro/Zepbound) for binge eating are underway. Long-term outcomes — beyond 6 months — are largely unknown.
So when I prescribe a GLP-1 for a patient with bulimia, I’m doing it off-label, with informed consent, with a careful eye on the literature, and with the understanding that this is an active clinical frontier. I never present these drugs as a cure or a “miracle.” I present them as a tool that, in the right patient, can do something nothing else has been able to do — quiet the urge before it starts.
Who Benefits — and Who Doesn’t
This is where the clinical judgment lives, and where my concierge psychiatry model matters most. A 15-minute med-check appointment cannot do what this conversation requires.
Patients who tend to benefit:
- Adults with longstanding bulimia or BED whose binges are clearly triggered by intense food cravings
- Patients with significant comorbid metabolic dysfunction — insulin resistance, prediabetes, obesity — where the GLP-1 is doing two jobs at once
- Patients already in psychotherapy and stable on an SSRI like fluoxetine, where the GLP-1 is added to an existing foundation
- Patients with bulimia in remission who are at high risk of relapse and need a maintenance tool
Patients I will not prescribe to:
- Anyone with a current or recent history of anorexia nervosa, restrictive eating, or BMI in the underweight range
- Patients whose bulimia is primarily driven by trauma, identity, or interpersonal dynamics rather than craving — the medication does nothing for those drivers and may mask the work that needs to happen
- Patients with severe electrolyte abnormalities from active purging until they’re medically stabilized
- Patients who appear to want the drug as a tool for further weight loss in a body that is already at or below a healthy weight
That last category is the one I worry about most. Bulimia can flip into anorexia. A drug that further suppresses appetite in someone whose appetite is already a battleground can be the trigger for that flip. I have refused to prescribe GLP-1s to patients who came to me asking specifically for them, and I will continue to.
What I Monitor
When a patient with bulimia goes on a GLP-1 in my practice, the appointment cadence changes. We meet every two weeks for the first two months, then monthly. We’re tracking:
- Weight trajectory — too fast a drop is a red flag, not a success
- Electrolytes, especially potassium and magnesium — bulimia depletes them, and GLP-1 GI side effects can mimic the very nausea that follows a purge
- Eating-disorder cognitions — the binge stopping is good; the patient becoming more preoccupied with thinness is not
- Mood — emerging data suggests GLP-1s may have antidepressant effects in some patients and dysphoric effects in others
- Substance use — many bulimic patients drink, and GLP-1s can interact uneasily with alcohol use, especially during a detox period
The patient and I also have an explicit agreement before we start: if the bulimia disappears but a new restrictive pattern emerges, we stop the medication. That conversation happens before we write the first prescription, not after.
How This Fits With Standard Treatment
A GLP-1 is not a replacement for the things that have always worked in bulimia — CBT, family-based therapy where appropriate, an SSRI (usually fluoxetine, the only FDA-approved drug for bulimia), nutritional rehabilitation, and treatment of comorbid depression and anxiety.
What a GLP-1 can do is reduce the volume of the urges enough that the therapy and the SSRI can finally do their work. For many patients, the binge-purge cycle has been so loud, so consuming, that they can’t access higher-order cognitive tools in the moment. Quiet the noise, and CBT becomes possible. That’s the synergy I’m seeing.
I integrate the medication management with the therapy in the same provider — me — because as both a board-certified psychiatrist and psychotherapist, I can hold both threads in one conversation. That continuity matters in eating disorder treatment more than almost anywhere else in psychiatry.
Frequently Asked Questions
Is Ozempic FDA-approved for bulimia?
No. No GLP-1 medication is FDA-approved for bulimia or binge eating disorder. The only FDA-approved medication for bulimia is fluoxetine (Prozac). When I prescribe a GLP-1 for an eating disorder, it is off-label, based on emerging clinical evidence and individualized risk-benefit analysis.
Can a GLP-1 trigger anorexia in someone with bulimia?
It can — and that’s the single biggest risk I monitor. Bulimia and anorexia exist on a continuum, and a substantial minority of patients move between them over the course of an illness. A medication that suppresses appetite can tip a vulnerable patient into restriction. This is why these medications should never be prescribed to patients with eating disorders by a clinician who isn’t actively monitoring weight, eating patterns, and cognitions every few weeks.
Should my primary care doctor or weight-loss clinic prescribe a GLP-1 if I have bulimia?
In my view, no — not without a psychiatrist involved. A primary care physician or med spa is not equipped to monitor for the specific risks GLP-1s pose in eating disorders. If you have a history of bulimia, BED, or anorexia and you’re being offered a GLP-1, I would strongly recommend a psychiatric evaluation before you start.
What about telehealth — can you prescribe across Florida?
Yes. I see patients across Florida via telehealth. For GLP-1 management in the context of an eating disorder, the appointments are longer and more frequent than a typical telehealth med check — usually 60 minutes, every two weeks initially. That cadence is part of what makes safe prescribing possible.
How long would I stay on a GLP-1 for bulimia?
Honestly, we don’t know yet. Some patients use them as a 6–12 month bridge while CBT and an SSRI take hold, then taper off. Others appear to need ongoing maintenance, much like someone with major depression on long-term antidepressant treatment. The decision is individualized, made together, and revisited every few months.
If you have bulimia or binge eating disorder and you’re trying to figure out whether a GLP-1 is right for you — or whether it’s right for you given that someone else has already prescribed it — I’d be glad to help you think it through carefully. This is exactly the kind of complex, fast-moving clinical question my practice was built for.
Learn more about Dr. Agresti, explore all services, or contact our office to discuss your needs.
Call 561-760-4107 or visit 44 Cocoanut Row, Suite M-202, Palm Beach, FL 33480. Telehealth available statewide.